Print
Email
Print Edition StoriesMonday, February 25, 2008
Clarus closes $660M second fund
Life sciences venture capital firm Clarus Ventures LLC reports closing a $660 million fund in limited partner commitments.
Clarus Lifesciences II LP is the second investment fund formed by Clarus Ventures since the firm was established in 2005. The firm plans to invest $20 million to $60 million in biotechnology, specialty pharmaceutical and medical technology companies developing products for the treatment of human diseases, Clarus officials said.
The firm, which operates offices in Cambridge and San Francisco, has $1.2 billion under management and has committed 90 percent of its first fund.
In 2005, Clarus Ventures, which invests in biopharmaceuticals and medical technology, closed its inaugural fund of $500 million.
Clarus was founded by Nicholas Galakatos, Dennis Henner, Robert Liptak, Nicholas Simon, Michael Steinmetz, and Kurt Wheeler. Galakatos was a co-founder and key executive with Millennium Pharmaceuticals. He also helped co-found Predictive Medicine and Transform Pharmaceuticals. Henner is a former executive with Genentech, and has been an investor in several life sciences companies on the West Coast.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
